Page last updated: 2024-09-03

gefitinib and protac-3

gefitinib has been researched along with protac-3 in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(protac-3)
Trials
(protac-3)
Recent Studies (post-2010) (protac-3)
5,2315662,919605

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Chen, X; Cheng, M; Han, X; Jin, J; Liu, J; Lu, K; Meng, F; Wang, L; Xie, L; Xiong, Y; Yu, X1
Cheng, M; Jin, J; Liu, J; Lu, K; Shen, Y; Xiong, Y; Yu, X; Zhong, Y1

Other Studies

2 other study(ies) available for gefitinib and protac-3

ArticleYear
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Journal of medicinal chemistry, 2020, 02-13, Volume: 63, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mutation; Protein Kinase Inhibitors; Proteolysis; Signal Transduction; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein

2020
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
    Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

    Topics: EGF Family of Proteins; ErbB Receptors; Humans; Phosphatidylinositol 3-Kinases; Proteolysis; Ubiquitin-Protein Ligases

2022